A Phase I, Randomized, Single-Blind, Controlled, Single Center Study to Evaluate the Safety and Immunogenicity of the NVGH Glycoconjugate Vaccine Against S. Typhi in Adult Subjects 18 to 40 Years of Age.
Phase of Trial: Phase I
Latest Information Update: 13 Jul 2013
At a glance
- Drugs Typhoid vaccine Vi conjugate (Primary) ; Typhoid vaccine Vi-polysaccharide
- Indications Typhoid
- Focus Adverse reactions; Pharmacodynamics
- 12 Jun 2012 Additional lead trial investigator (Pierre VanDamme) identified as reported by ClinicalTrials.gov.
- 23 Nov 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 24 May 2010 New trial record